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Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the current coro-
navirus disease (COVID-19) pandemic [1]. Over the last months, a plethora of novel research articles
has been published, dealing with multiple aspects and manifestations of the disease. Increasing evidence
points to a central role of endothelial cells (ECs) in SARS-CoV-2 infection [–5]. Early studies have already
indicated increased expression of vascular and inflammatory factors (such as VCAM-1, IL-8 or MCP-1) in
COVID-19 lung tissue [2]. Such markers of endothelial dysfunction and altered endothelial cell integrity
are important predictors of a poor outcome in SARS-CoV-2 infections [6], and they are associated with
pulmonary edema, intravascular thrombosis and acute respiratory distress syndrome (ARDS).
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Take home message:  
Elevated levels of several endothelial markers including CD31, VEGFR-2, ICAM-1, VCAM-1, E-selectin, 
P-selectin and vWF in patients’ lung tissue and circulation support an important role of the 
pulmonary endothelium in local and systemic COVID-19 pathology.  
    
To the Editor:   
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the current coronavirus 
disease (COVID-19) pandemic (1).  Over the last months, a plethora of novel research articles has 
been published, dealing with multiple aspects and manifestations of the disease. Increasing evidence 
points to a central role of endothelial cells (ECs) in SARS-CoV-2 infection (2-5). Early studies have 
already indicated increased expression of vascular and inflammatory factors (such as VCAM-1, IL-8 or 
MCP-1) in COVID-19 lung tissue (2). Such markers of endothelial dysfunction and altered endothelial 
cell integrity are important predictors of a poor outcome in SARS-CoV-2 infections (6), and they are 
associated with pulmonary edema, intravascular thrombosis and acute respiratory distress syndrome 
(ARDS). The pulmonary endothelium is crucial for regulation of vascular tone, inflammatory 
responses, coagulation/fibrinolysis and maintenance of vascular homeostasis and permeability. 
Disturbances of these tightly regulated processes may directly contribute to morbidity and mortality. 
However, the exact mechanisms leading to pulmonary vasculopathy in COVID-19 are still unclear. 
Here, we provide an analysis of several important vascular markers implicated in the inflammatory 
response (E-Selectin, intercellular cell adhesion molecule (ICAM-1), vascular cell adhesion molecule 
(VCAM1)), maintenance of microvascular integrity (CD31, VEGFR-2), platelet activation and 
coagulation (P-Selectin, von Willebrand factor (vWF)) in lung tissue and plasma samples of COVID-19 
patients.    
Lung tissue samples were collected post-mortem from 19 critically ill COVID-19 patients and 11 age 
and sex-matched autopsy controls without underlying lung pathology. The median age was 79 years 
for COVID-19 and 75 years for the respective autopsy controls (Figure 1A). The study protocol and 
tissue usage were approved by the ethics commission of the Medical University of Graz (EK-number: 
32-362 ex 19/20). RNA was isolated from homogenized lung tissue and cDNA synthesis and 
quantitative real-time PCR (qPCR) were performed as described previously (7). Immunofluorescence 
staining was performed on formalin fixed paraffin embedded lung tissue from corresponding COVID-
19 patients and autopsy controls using vWF (1:1000, #M0616, Agilent, Santa Clara, CA) and CD45 
(1:250, # 10558, Abcam, Cambridge, UK) and secondary antibody labeled with Alexa Fluor 555 or 
Alexa Fluor 488 (1:500, Thermofisher Scientific, Waltham, MA) respectively.   Plasma samples were 
collected from 21 critically ill COVID-19 patients and 22 healthy controls at Hannover Medical School, 
Hannover, Germany and from the Department of Clinical Immunology and Transfusion Medicine at 
the Justus-Liebig University of Giessen, Germany. The median age was 59 years for COVID-19 patients 
and 61 years for the respective controls. 90% of patients and 89% of the controls were male. All 
COVID-19 patients were severely ill and required use of vasopressors and mechanical ventilation 
(Figure 1B). Investigations were approved by the local ethics committee (Hannover samples: 
SEPSIS/ARDS Registry 8146_BO_K_2018, Giessen samples: ethic votum no.: 05/00) and written 
informed consent was obtained from all participants or their next-of-kin. Plasma levels of E-selectin, 
P-selectin, ICAM-1, VCAM-1 and CD31 were determined in a LEGENDplex™ Assay. Sandwich High 
Sensitivity ELISA kits were used to quantify vWF (#EHVWF, Thermofisher Scientific) and IL-6, IL-8, 
TNFα and MCP-1 (Biolegend, San Diego, CA) plasma levels. Statistical analysis was performed in R 
(version number 4, www.r-project.org). Data are expressed as single data points with boxplot overlay 
indicating median and interquartile range.  Different groups were compared using Wilcoxon Mann-
Whitney U-test. Correlations were performed using Spearman’s rank correlation. 
Gene expression analysis revealed an upregulation of ICAM-1, vWF and VEGFR2 (KDR) in COVID-19 
lung tissue compared to control tissue (Figure 1C). Immunofluorescence staining for inflammatory 
cell marker CD45 and vWF revealed increased extravasation of inflammatory cells and a prominent, 
more diffuse vWF signal (Figure 1D) in COVID-19 compared to control lungs. The latter may reflect 
increased vWF shedding, an assumption supported by elevated levels of circulating vWF (Figure 1E). 
Next to vWF, we found significantly increased levels of VCAM-1, E-Selectin, and CD31 in COVID-19 
plasma (Figure 1E), indicating endothelial cell activation/dysregulation in COVID-19. In addition, 
levels of inflammatory cytokines IL-6, IL-8, MCP-1 and TNFα were significantly increased in COVID-19 
plasma (Figure 1F). Detailed correlation analysis revealed strong associations between some of the 
endothelial derived markers but only weak associations with age or general inflammatory 
parameters such as CRP (Figure 1G). D-dimer levels strongly correlate with soluble vWF, while 
increased PTT correlates with shedding of surface markers ICAM1, E-selectin and CD31 (Figure 1G, H). 
Fibrinogen levels correlate with increased P-selectin (Figure 1H). In addition, plasma levels of IL-8 
were strongly associated with circulating vWF levels (Figure 1H). In summary, local as well as 
systemic, circulating inflammatory markers coincide with various markers revealing endothelial 
activation and damage in COVID-19 patients.  
The pulmonary endothelium is a tightly regulated organ, comprising a great variety of functions, both 
under physiological and pathological conditions. Inflammatory cell recruitment to the lung is 
mediated by selectins (E-selectin, P-selectin) and cell adhesion molecules (ICAM-1, VCAM-1) 
expressed on the surface of endothelial cells. These molecules are either stored intracellularly and 
released (P-selectin) or arise from de novo synthesis (ICAM-1, VCAM-1, E-selectin) in response to a 
specific cytokine milieu (8). An excessive production of pro-inflammatory cytokines, a so-called 
“cytokine storm”, has been previously reported in severe COVID-19 (9-11) and confirmed here. The 
cytokine storm contributes to a switch from a protective to an inflammatory EC phenotype, 
associated with vascular leakage, tissue injury and immuno-thrombosis. Shedding of adhesion 
molecules indicates a highly activated endothelium, while elevated levels of plasma CD31 are 
additionally linked to EC apoptosis (8). Given the increased circulating levels of adhesion molecules 
(E-selectin, VCAM-1, ICAM-1) and CD31, our data suggest that the endothelium is highly 
inflammatory and partly damaged in severe COVID-19. This notion is corroborated by local 
alterations in vWF mRNA and protein levels as well as its patchy and diffuse distribution in COVID-19 
lungs. The correlation of vWF and IL-8, as seen in our data, implies a concomitant release of these 
proteins from Weibel-Palade bodies which ensures rapid reaction to damage and recruitment of 
inflammatory cells, further highlighting endothelial stress and activation in critically ill COVID-19 
patients. Simultaneous upregulation of VEGFR-2 expression might display compensatory 
angiogenesis, which has been observed in COVID-19 patients of various disease severity (2). Of note, 
increased expression of VCAM-1, IL-8 and MCP-1 in the lung tissue was shown to be specific for 
COVID-19 compared to ARDS due to influenza (2). Overall, our data showing local de novo synthesis 
of endothelial activation and damage markers, suggest that the lung contributes to the pool of these 
proteins in plasma. However, the magnitude and the rate of lung contribution in relation to other 
organs has to be addressed in future studies. 
In general, the resting pulmonary endothelium supports maintenance of fibrinolysis (9). However, 
the presence of proinflammatory mediators drive a pro-coagulant state that finally leads to over-
activation of coagulation and thrombosis, as seen in patients with COVID-19. We found that not only 
circulating levels of vWF but also its expression in the lung is strongly elevated in severe COVID-19 
patients. vWF is stored in and rapidly released from Weibel-Palade bodies upon EC injury. It locally 
promotes platelet adhesion and thrombus formation (8). Several recent publications suggested an 
important role of vWF in COVID-19 vasculopathy (12, 13) and for residual pulmonary obstruction 
after acute pulmonary embolism (14). Importantly, elevated vWF levels were reported to be 
associated with severity of illness and mortality in patients infected with SARS-CoV2 (12). A strong 
positive correlation between circulating vWF and D-Dimer, a marker of coagulation activation and 
poor prognosis in severe COVID-19, underpins the imbalance between pro-and anti-coagulatory 
processes directly related to endothelial dysfunction in critically ill COVID-19. A recent study also 
highlighted the use of IL-8 to discriminate COVID-19 patients with high mortality (11). The recent 
findings suggest lower circulating cytokine levels in COVID-19 ARDS compared to non-COVID-19 
ARDS, while an increased local prothrombotic state, accompanied by hypofibrinolysis in severe 
COVID-19 patients has been described (15). Together, cumulative assessment of several markers of 
EC activation/damage and inflammation might be a valuable tool to assess the immunothrombosis 
status and thus risk estimation of embolic vessel occlusion in hospitalized patients with COVID-19. 
This study is limited by the lack of a non-COVID-19 disease controls, however, our data argue in 
favour of an important role of the pulmonary endothelium in the systemic immunopathology 
underlying COVID-19. In line with other reports, our work provides a link between endothelial 
dysfunction and pulmonary coagulopathy seen in severe COVID-19 patients. Although further studies 
are required to fully understand endothelial changes in the onset, progression and resolution of the 
disease, our data unravel several EC markers which participate in inflammatory cell recruitment, 
maintenance of EC integrity and coagulation in critically ill COVID-19 patients. While, integrating such 
markers into clinical practice may allow for a better prediction of COVID-19 outcome, further 
prospective studies using larger cohorts are warranted.  
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Figure Legend:  
(A) Patient characteristics of COVID-19 and Control lung autopsy samples. The median with minimum 
to maximum (min-max) values are shown. (B) Patient characteristics and clinical parameters of the 
COVID-19 cohort used to assess plasma levels of EC and inflammatory markers. The median with 
minimum to maximum (min-max) values are shown. (C) Quantitative real-time PCR analysis of 
important endothelial markers in COVID-19 (n=19) and control (n=11) lung tissue homogenates. 
Heatmap representation of relative expression changes. z-stacks are shown; KDR/VEGFR2: vascular 
endothelial growth factor receptor 2; VWF: von Willebrand factor; CD31/PECAM1: Platelet And 
Endothelial Cell Adhesion Molecule 1; VCAM1: Vascular Cell Adhesion Molecule 1; ICAM1: 
Intercellular Adhesion Molecule 1; SELP: P-Selectin. (D) Immunofluorescence staining of VWF (red) 
and inflammatory marker CD45 (green) in Control and COVID-19 lung tissue. White arrowheads 
highlight inflammatory cells. White asterisks indicate auto-fluorescent extracellular matrix. scalebar = 
50µm. (E,F) Circulating levels of (E) endothelial markers ICAM1, VCAM1, E-Selectin, CD31, P-Selectin 
and VWF, and (F) inflammatory mediators Interleukin (IL)-6, monocyte-chemoattractant protein 
(MCP)-1, IL-8 and tumour-necrosis factor α (TNFα) in the plasma of COVID-19 patients  (n= 21) and 
healthy controls (n=22); *p< 0.05, **p< 0.01, *** p< 0.001, **** p< 0.0001. G) Correlation matrix of 
clinical parameters (CRP: C-reactive protein, PCT: procalcitonin, ptt: partial thromboplastin time, 
BMI: body mass index, SOFA: sequential organ failure assessment score) and ICAM1, VCAM1, E-
Selectin, CD31, P-Selectin, VWF, IL-6, MCP1, IL-8 and MCP-1 circulating levels in COVID-19 patients. 
Dot size and colour correspond to the correlation coefficient, circled dots indicate significance using a 
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Age (years) 79 (54-94) 75 (59-84)
Sex  (male %) 65 55
CRP (mg/l) 114 (31-358) 55 (3-340)
D-Dimer (mg/l) 3 (0.6-10) -
Fibrinogen (mg/ml) 5 (3-6) 3 (2-5)




Age (years) 59 (19-82) 61 (19-78)
Sex  (male %) 90 89
BMI (kg/m2) 29 (15-62) -
CRP (mg/l) 151 (68-292) -
PCT (µg/l) 1 (0.1-66) -
D-Dimer (mg/l) 4 (1-35) -
Fibrinogen (mg/ml) 7 (4-9) -
PTT (s) 36 (26-55) -
SOFA score 13 (9-17) -
Thrombocytes (/nl) 247 (99-581) -
Mechanical ventilation 100% -
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